FDA Approves Liquid Biopsy for NSCLC
The FDA has approved FoundationOne Liquid CDx as a companion diagnostic for non-small cell lung cancer (NSCLC) patients with specific genetic mutations. The approval highlights the increasing integration of molecular diagnostics with traditional imaging in cancer care pathways. This allows for less invasive testing to guide targeted therapies.
- This specific FDA approval for FoundationOne Liquid CDx identifies patients with *EGFR* exon 20 insertion mutations, making them eligible for the targeted therapy mobocertinib (Exkivity). The test analyzes circulating cell-free DNA from a blood sample to assess 324 genes. - Liquid biopsies offer significant advantages over traditional tissue biopsies, with studies showing they can return results on average 26.8 days faster. This quicker turnaround allows oncologists to make faster treatment decisions, which is critical for patients with advanced NSCLC. - This approval aligns with a major site-of-care shift, as approximately 40% of all radiology volume has moved from hospitals to outpatient settings. This trend is driven by payers incentivizing the use of more cost-effective freestanding imaging centers and health systems developing their own outpatient strategies to capture this growth. - A study on the financial impact of this shift suggests that moving just 10% of hospital-based care to outpatient settings could save an estimated $125 billion annually across the U.S. healthcare system. - The global mobile imaging services market is a competitive landscape featuring key players like Alliance HealthCare Services, Mednax, and Shared Medical Services, with North America holding the largest market share at over 40% in 2024. The market was valued at $2.09 billion in 2024 and is projected to grow to $2.79 billion by 2033. - This diagnostic advancement comes as radiology faces significant operational pressures, including a workforce shortage that saw job board positions leap from 611 in 2010 to over 14,000 in 2022. This staffing gap is a key driver for adopting efficiency-enhancing technologies and workflows like teleradiology and AI. - Federal reimbursement policies are accelerating these trends; CMS has implemented site-neutral payment policies to counter higher fees at hospital-owned off-campus sites and continues to adjust the Medicare Physician Fee Schedule, which has seen a decade of negative adjustments for diagnostic radiology. - The FDA is rapidly clearing AI-powered tools for radiology, with the number of approved devices reaching 1,039 by late 2025, accounting for nearly 80% of all approved AI medical technologies. This wave of innovation is focused on improving diagnostic accuracy and reducing radiologist workload.
